XML 21 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Cumulative Effect Adjustment
Accumulated deficit
Cumulative Effect Adjustment
Total
Balance (in shares) at Dec. 31, 2017 41,612,395            
Balance at the beginning of the period at Dec. 31, 2017 $ 42 $ 966,534 $ 3,969 $ 3,266 $ (814,108) $ 3,266 $ 156,437
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock related to equity offerings (in shares) 4,600,000            
Issuance of common stock related to equity offering $ 5 117,911         117,916
Issuance of common stock related to acquisition (in shares) 3,500,907            
Issuance of common stock related to acquisition $ 3 155,857         155,860
Exercise of options (in shares) 633,973            
Exercise of options $ 1 10,867         10,868
Restricted stock vesting and issuance (in shares) 119,691            
Restricted stock vesting and issuance, net             0
Issuance of common stock in connection with an employee stock purchase plan (in shares) 139,181            
Issuance of common stock in connection with an employee stock purchase plan   2,787         2,787
Share-based compensation expense   33,252         33,252
Receivable from investor   929         929
Net loss         (128,081)   (128,081)
Comprehensive loss     (2,507)       (2,507)
Balance (in shares) at Dec. 31, 2018 50,606,147            
Balance at the end of the period at Dec. 31, 2018 $ 51 1,288,137 1,462   (938,923)   350,727
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock related to equity offerings (in shares) 10,102,899            
Issuance of common stock related to equity offering $ 10 323,746         323,756
Equity component of convertible notes, net   119,482         119,482
Exercise of options (in shares) 949,887            
Exercise of options $ 1 18,275         18,276
Restricted stock vesting and issuance (in shares) 169,792            
Restricted stock vesting and issuance, net             0
Issuance of common stock in connection with an employee stock purchase plan (in shares) 107,145            
Issuance of common stock in connection with an employee stock purchase plan   3,577         3,577
Share-based compensation expense   42,134         42,134
Net loss         (251,576)   (251,576)
Comprehensive loss     (12,046)       (12,046)
Balance (in shares) at Dec. 31, 2019 61,935,870            
Balance at the end of the period at Dec. 31, 2019 $ 62 1,795,351 (10,584)   (1,190,499)   594,330
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock related to equity offerings (in shares) 542,470            
Issuance of common stock related to equity offering $ 1 28,091         28,092
Issuance of common stock related to acquisition (in shares) 845,364            
Issuance of common stock related to acquisition $ 1 42,868         42,869
Issuance of common stock related to rights exchange (in shares) 2,821,176            
Issuance of common stock related to rights exchange $ 3 150,525         150,528
Exercise of options (in shares) 3,268,452            
Exercise of options $ 3 70,176         70,179
Restricted stock vesting and issuance (in shares) 180,028            
Restricted stock vesting and issuance, net             0
Issuance of common stock in connection with an employee stock purchase plan (in shares) 124,736            
Issuance of common stock in connection with an employee stock purchase plan   5,303         5,303
Share-based compensation expense   70,325         70,325
Receivable from investor   9,107         9,107
Other         (218)   (218)
Net loss         (438,160)   (438,160)
Comprehensive loss     (50,373)       (50,373)
Balance (in shares) at Dec. 31, 2020 69,718,096            
Balance at the end of the period at Dec. 31, 2020 $ 70 $ 2,171,746 $ (60,957)   $ (1,628,877)   $ 481,982